TPF Plus Radiotherapy and Cetuximab to Avoid Total Laryngectomy in Patients With Larynx Cancer

Head and Neck Cancer Clinical Trial

Official title:

A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00765011
• Other study ID #: TTCC-2007-02
• Status: Completed
• Phase: Phase 2
• Start date: October 2008
• Est. completion date: May 12, 2015

Study information

• Verified date: April 2019
• Source: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy.

Description:

This study is being sponsored by a cooperative medical group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: May 12, 2015
• Est. primary completion date: February 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Signed Informed Consent Form.

2. Men or women, age (18 and 70).

3. ECOG scale:0-1.

4. Life expectancy superior to 3 months.

5. Larynx squamous carcinoma histologically demonstrated.

6. Patients with larynx squamous carcinoma, stage III-IVA, with resectable disease whose surgery will imply a total laryngectomy. The T should be a T3, T4A, or a T2 not candidate for a partial laryngectomy. In case of T2 of any of both locations it will be required a III or IVA stadium.

7. Patients to be able to receive treatment with TPF followed by normofractionated radiotherapy with cetuximab.

8. Measurable disease (OMS criteria).

9. Neutrophils superior or equal to 1500/mm3, platelets superior or equal to 150.000/mm3, hemoglobin superior or equal to 10 g/dl.

10. Adequate renal function: creatinin lower or equal to 120 µmol/l (1,4mg/dl)

11. Adequate hepatic function: bilirubin lower or equal to 1 x UNL, AST and ALT lower or equal to 2,5 UNL, alkaline phosphatase lower or equal to 5 UNL.

12. Seric calcium adjusted to albumine lower or equal to 1,25 UNL.

13. Adequate nutritional condition: loss of weight <20% with relation to the theoretical weight and albumin superior or equal to 35 g/L.

14. Use of an effective contraceptive method.

Exclusion Criteria:

1. Metastatic disease

2. Surgical treatment, previous radiotherapy and/or chemotherapy for the study disease.

3. Other tumour locations in H&N that are not larynx.

4. Other stages that are not III or IVa without metastasis and resectable disease.

5. The following cases, which will be considered candidates for radical surgery, will not be included in the study:

• Tumors of the subglottis.

• Tumors of glottis or supraglottis with subglottal extension

• Tumor that destroys the thyroid cartilage and/or cricoid and it extends to thyroid gland or soft necks's tissues.

• Tumor of supraglottis with a superior extension to 1 cm towards the tongue base (the extension will be measured since the vallecula).

6. Other previous and/or synchronic squamous carcinoma.

7. Diagnosis of another neoplasia in the last 5 years, excepting carcinoma in situ of uterine neck and/or a cutaneous carcinoma basocellular properly treated.

8. Active infection(at needs endovenous antibiotics), including active tuberculosis and diagnosed HIV.

9. Not controlled hypertension defined as arterial systolic tension superior or equal to 180 mm Hg and/or diastolic arterial tension superior or equal to 130 mm Hg baseline.

10. Pregnancy or breastfeeding.

11. Immunity systemic treatment, chronic and concomitant, or hormonal treatment of the cancer.

12. Other antineoplasic concomitant treatments.

13. Coronary clinically significant arteriopathy or precedents of myocardial infarction in the last 12 months or high risk of not controlled arrhythmia or cardiac not controlled insufficiency.

14. Pulmonary obstructive chronic disease that had needed 3 or more hospitalizations in the last 12 months.

15. Active non controlled peptic ulcer.

16. Presence of a psychological or medical disease that could prevent to accomplish the study by the patient or to grant his/her signature in the informed consent form.

17. Known drugs abuse (excepting excessive consumption of alcohol).

18. Known allergic reaction to some of the components of the treatment of the study.

19. Previous treatment with monoclonal antibodies or other transduction of the sign inhibitors or treatment directed against the EGFR.

20. Any experimental treatment in 30 days before entry in the study.

Related Conditions & MeSH terms

• Head and Neck Cancer
• Head and Neck Neoplasms
• Laryngeal Neoplasms

Intervention

Drug:
• TPF, radiotherapy and cetuximab
3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days

Procedure:
• H&N surgery
Rescue surgery

Locations

Country	Name	City	State
Spain	Hospital Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Clínic i Provincial de Barcelona	Barcelona
Spain	Hospital San Pedro de Alcántara	Cáceres
Spain	Hospital Dr.Josep Trueta (ICO Girona)	Girona
Spain	Hospital Universitario Virgen de las Nieves	Granada
Spain	Oncogranada	Granada
Spain	Hospital Duran i Reynals	L'Hospitalet de Llobregat	Barcelona
Spain	Hospital Xeral Calde	Lugo
Spain	Hospital Gregorio Marañon	Madrid
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Universitario San Carlos	Madrid
Spain	Hospital de Manresa	Manresa	Barcelona
Spain	Hospital Son Llátzer	Palma De Mallorca
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Hospital Universitario la Fe de Valencia	Valencia
Spain	Hospital Clínico Universitario de Zaragoza	Zaragoza
Spain	Hospital Miguel Servet	Zaragoza

Sponsors (1)

Lead Sponsor	Collaborator
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Specific survival free of total laryngectomy	Time from the start of TPF treatment to death caused by the disease or by the treatment of the disease, or even to surgery involving total laryngectomy. Deaths caused by other reasons were considered "censored" data on the date of death.	Three years after the end of treatment with radiotherapy and cetuximab

External Links

•   This site would like to expose the activities of the group and at the same time serve as an information and communication tool of this pathology for professionals and patients.